Reproxalap, under investigation for the treatment of dry eye disease, met the primary endpoint in the phase 3 TRANQUILITY-2 trial, Aldeyra Therapeutics announced in a press release.
Reproxalap, a small-molecule modulator of reactive aldehyde species, was superior to vehicle in two measures, Schirmer’s test change from baseline (P = .001) and 10 mm or greater Schirmer test responder proportions (P < .0001).
“The positive results of TRANQUILITY-2 are expected to complete the most comprehensive dry eye disease NDA submission to date,” Todd C. Brady, MD, PhD, Aldeyra president